MX340064B - Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos. - Google Patents
Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos.Info
- Publication number
- MX340064B MX340064B MX2012005921A MX2012005921A MX340064B MX 340064 B MX340064 B MX 340064B MX 2012005921 A MX2012005921 A MX 2012005921A MX 2012005921 A MX2012005921 A MX 2012005921A MX 340064 B MX340064 B MX 340064B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- azaadamantane derivatives
- derivatives
- azaadamantane
- Prior art date
Links
- WENISBCJPGSITQ-UHFFFAOYSA-N 1-azatricyclo[3.3.1.13,7]decane Chemical class C1C(C2)CC3CC1CN2C3 WENISBCJPGSITQ-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000651 prodrug Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Abstract
La invención se refiere a una composición farmacéutica que comprende un compuesto seleccionado a partir del grupo que consiste en: (a) (4s)-4-(5-fenil-[1, 3,4]-tiadiazol-2-iloxi)-1aza- triciclo-[3.3.1.13,7]-decano; (b) 1-óxido de (4s)-4-(5-fenil-[1,3, 4]-tiadiazol-2-iloxi)-1-aza-triciclo-[3.3.1.13.7]-decano; (c) (4r)-4-(5-fenil-[1,3,4]-tiadiazol-2-iloxi)-1-aza-tricciclo [3.3.1.13.7]-decano; y (d) combinaciones de los mismos, y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85699206P | 2006-11-06 | 2006-11-06 | |
US90814307P | 2007-03-26 | 2007-03-26 | |
US11/935,257 US20080122023A1 (en) | 2006-11-29 | 2007-11-05 | Method of manufacturing cmos image sensor |
US11/935,157 US8314119B2 (en) | 2006-11-06 | 2007-11-05 | Azaadamantane derivatives and methods of use |
PCT/US2007/083687 WO2008058096A2 (en) | 2006-11-06 | 2007-11-06 | Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
MX340064B true MX340064B (es) | 2016-06-23 |
Family
ID=39594848
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012005921A MX340064B (es) | 2006-11-06 | 2007-11-06 | Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos. |
MX2009004813A MX2009004813A (es) | 2006-11-06 | 2007-11-06 | Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004813A MX2009004813A (es) | 2006-11-06 | 2007-11-06 | Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos. |
Country Status (29)
Country | Link |
---|---|
US (3) | US8314119B2 (es) |
EP (1) | EP2099795B1 (es) |
JP (4) | JP5275246B2 (es) |
KR (4) | KR20140054300A (es) |
CN (1) | CN103554107B (es) |
AU (1) | AU2007316480B2 (es) |
BR (1) | BRPI0718028A2 (es) |
CA (1) | CA2668962C (es) |
CO (1) | CO6210720A2 (es) |
CR (2) | CR10743A (es) |
DK (1) | DK2099795T3 (es) |
DO (3) | DOP2011000301A (es) |
EC (1) | ECSP099388A (es) |
ES (1) | ES2551117T3 (es) |
HK (1) | HK1133645A1 (es) |
IL (2) | IL198587A (es) |
MX (2) | MX340064B (es) |
MY (1) | MY148253A (es) |
NO (1) | NO20092181L (es) |
NZ (4) | NZ577474A (es) |
PH (1) | PH12013500745A1 (es) |
PL (1) | PL2099795T3 (es) |
PT (1) | PT2099795E (es) |
RU (2) | RU2450002C2 (es) |
SG (1) | SG176473A1 (es) |
TW (1) | TWI511729B (es) |
UA (1) | UA96961C2 (es) |
WO (1) | WO2008058096A2 (es) |
ZA (3) | ZA200903944B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20060437A1 (es) * | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
MX2010005483A (es) * | 2007-11-20 | 2010-06-11 | Merck Sharp & Dohme | Inhibidores de transcriptasa inversa no nucleosidos. |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
CN102459268A (zh) * | 2009-06-19 | 2012-05-16 | 雅培制药有限公司 | 二氮杂高金刚烷衍生物和其使用方法 |
GB0912946D0 (en) | 2009-07-24 | 2009-09-02 | Addex Pharmaceuticals Sa | New compounds 5 |
JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
US8912179B2 (en) * | 2010-09-02 | 2014-12-16 | Suven Life Sciences Limited | Heterocyclyl compounds as histamine H3 receptor ligands |
SG2014013460A (en) * | 2010-09-23 | 2014-09-26 | Abbvie Inc | Monohydrate of an azaadamantane derivative |
BR112013018726A2 (pt) | 2011-01-27 | 2016-10-25 | Novartis Ag | uso de ativadores de alfa 7 do receptor nicotínico de acetilcolina |
US8802693B1 (en) * | 2011-03-09 | 2014-08-12 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
AU2012232711B2 (en) | 2011-03-18 | 2016-04-28 | Novartis Ag | Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease |
AU2012230890A1 (en) | 2011-03-22 | 2013-09-26 | Amgen Inc. | Azole compounds as Pim inhibitors |
BR112014007485B1 (pt) | 2011-10-20 | 2022-05-31 | Novartis Ag | Métodos para prever responsividade terapêutica de um indivíduo a tratamento com um ativador do receptor de acetilcolina nicotínico alfa 7, e usos do referido ativador |
US20130317056A1 (en) * | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonists and methods of correlating comt snps |
US20130317054A1 (en) * | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
US20130317055A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
BR112015013771B1 (pt) | 2012-12-11 | 2022-10-04 | Novartis Ag | Composição que compreende um ativador do receptor alfa 7, nicotínico de acetilcolina (nachr) como biomarcador preditivo de resposta ao tratamento de ativador do dito receptor |
ES2883232T3 (es) | 2013-01-15 | 2021-12-07 | Novartis Ag | Uso de agonistas del receptor nicotínico de acetilcolina alfa 7 |
ES2865736T3 (es) | 2013-01-15 | 2021-10-15 | Novartis Ag | Uso de agonistas del receptor de acetilcolina nicotínico alfa 7 |
CN105263492B (zh) | 2013-01-15 | 2018-04-10 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
US8969562B2 (en) * | 2013-03-12 | 2015-03-03 | Abbvie, Inc. | Azaadamantane formate ester and process for preparing azaadamantane derivatives |
JP6612874B2 (ja) | 2014-12-16 | 2019-11-27 | アクソファント サイエンシーズ ゲーエムベーハー | α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物 |
RU2017145964A (ru) | 2015-06-10 | 2019-07-10 | Аксовант Сайенсиз Гмбх | Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов |
JP2018523707A (ja) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物 |
CA3007412C (en) * | 2015-12-10 | 2021-08-24 | Ptc Therapeutics, Inc. | The use of 1,4-disubstituted pyridazine compounds to treat huntington's disease |
CN111065626A (zh) | 2017-06-05 | 2020-04-24 | Ptc医疗公司 | 用于治疗亨廷顿氏舞蹈病的化合物 |
EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
AU2018309187C1 (en) | 2017-08-04 | 2023-09-07 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
JP6638716B2 (ja) * | 2017-11-20 | 2020-01-29 | コベルコ建機株式会社 | 建設機械のカーボディ |
JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための化合物 |
EA202092896A1 (ru) | 2018-06-27 | 2021-04-13 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
CN109232474B (zh) * | 2018-09-27 | 2021-08-06 | 武汉尚赛光电科技有限公司 | 1,2,4-噻二唑类化合物及其制备方法和用途 |
CN113660936A (zh) * | 2019-02-04 | 2021-11-16 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
US11130743B2 (en) | 2019-02-21 | 2021-09-28 | Marquette University | Heterocyclic ligands of PAR1 and methods of use |
WO2020172609A1 (en) * | 2019-02-21 | 2020-08-27 | Marquette University | Heterocyclic ligands of par1 and methods of use |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2514006A1 (fr) | 1981-10-05 | 1983-04-08 | Nativelle Sa Ets | Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique |
EP0088484A1 (en) | 1982-02-04 | 1983-09-14 | Fbc Limited | Herbicidal thiadiazolyl N-aminoureas |
GB8523211D0 (en) | 1985-09-19 | 1985-10-23 | Beecham Group Plc | Compounds |
EP0350130A3 (en) | 1988-07-07 | 1991-07-10 | Duphar International Research B.V | New substituted 1,7-annelated 1h-indazoles |
US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
JPH06506467A (ja) | 1991-03-08 | 1994-07-21 | ローヌ−プーラン ローラー インターナショナル(ホウルディングス) インコーポレイテッド | 多環式三級アミンポリ芳香族スクアレンシンセターゼインヒビター |
US5280028A (en) | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
US5434151A (en) | 1992-08-24 | 1995-07-18 | Cytomed, Inc. | Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase |
US5840903A (en) | 1992-07-27 | 1998-11-24 | G. D. Searle & Co. | 4-aminomethyl-1-azaadamantane derived benzamides |
JP3235913B2 (ja) | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | アミノ安息香酸誘導体 |
US5399562A (en) | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
US5672709A (en) | 1994-10-24 | 1997-09-30 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
US5852037A (en) | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
US5998434A (en) | 1995-12-06 | 1999-12-07 | Eli Lilly And Company | Composition for treating pain |
WO1998027983A1 (en) | 1996-12-20 | 1998-07-02 | Novo Nordisk A/S | A method of treating hypercholesterolemia and related disorders |
US7732163B2 (en) | 1997-08-21 | 2010-06-08 | Board Of Trustees Of The University Of Arkansas | Extracellular serine protease |
US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
US8236500B2 (en) | 1997-10-23 | 2012-08-07 | The United States Of America, As Represented By The Department Of Veterans Affairs | Promoter variants of the alpha-7 nicotinic acetylcholine receptor |
HU230154B1 (hu) | 1997-11-12 | 2015-09-28 | Bayer Intellectual Property Gmbh | Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására |
US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
US5986100A (en) * | 1998-04-02 | 1999-11-16 | Crooks; Peter Anthony | Pharmaceutical compositions and methods for use |
US6057446A (en) | 1998-04-02 | 2000-05-02 | Crooks; Peter Anthony | Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds |
CA2317567A1 (en) * | 1998-04-02 | 1999-10-14 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions and methods for use |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
PT1083889E (pt) | 1998-06-01 | 2004-04-30 | Ortho Mcneil Pharm Inc | Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas |
RU2219179C2 (ru) | 1998-08-18 | 2003-12-20 | ЮСиБи С.А. | Азациклические соединения, фармацевтические композиции |
JP2002543201A (ja) * | 1999-05-04 | 2002-12-17 | ニューロサーチ、アクティーゼルスカブ | ヘテロアリールジアザビシクロアルカン類、その製造方法及びその使用方法 |
EP1185513A2 (en) | 1999-05-24 | 2002-03-13 | Targacept, Inc. | Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
WO2001040261A1 (en) | 1999-12-01 | 2001-06-07 | Ortho-Mcneil Pharmaceutical, Inc. | Method of diagnosing neurodegenerative disease |
JP2004502692A (ja) | 2000-07-04 | 2004-01-29 | ニューロサーチ、アクティーゼルスカブ | アリール及びヘテロアリールジアザビシクロアルカン類、その製造方法及びその使用方法 |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
JP4225787B2 (ja) | 2001-03-27 | 2009-02-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | N−アリール環状アミン誘導体およびそれを有効成分として含有する医薬 |
FR2832713B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
EP1463481A4 (en) | 2001-12-14 | 2008-06-25 | Targacept Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
JP2005524713A (ja) | 2002-05-07 | 2005-08-18 | ニューロサーチ、アクティーゼルスカブ | 新規ジアザビシクロビアリール誘導体 |
US7049374B2 (en) | 2002-07-18 | 2006-05-23 | Chevron U.S.A. Inc. | Heterodiamondoids |
EP1532144B1 (en) | 2002-08-14 | 2008-01-23 | Neurosearch A/S | quinuclidine derivatives and their use |
US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US7135454B2 (en) | 2003-04-16 | 2006-11-14 | Applied Research Systems Ars Holding N.V. | Use of SLURP-1 compositions for treating schizophrenia |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
JP2005232071A (ja) | 2004-02-19 | 2005-09-02 | Kanto Chem Co Inc | ピラゾール誘導体 |
JP2007535553A (ja) | 2004-04-29 | 2007-12-06 | アボット・ラボラトリーズ | アミノ−テトラゾール類縁体および使用方法 |
EA014419B1 (ru) | 2004-05-24 | 2010-12-30 | Эмджен Инк. | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения |
PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
FR2872165B1 (fr) | 2004-06-24 | 2006-09-22 | Sod Conseils Rech Applic | Nouveaux derives de pyrimido-benzimidazole |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
EP1794120B1 (en) | 2004-07-23 | 2012-04-11 | Nuada, LLC | Peptidase inhibitors |
DK1781265T3 (da) | 2004-08-25 | 2010-08-02 | Essentialis Inc | Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf |
DE602005025902D1 (de) * | 2004-10-15 | 2011-02-24 | Neurosearch As | Neue azabizyklische arylderivate und medizinische verwendung damit |
US20080153806A1 (en) | 2004-10-20 | 2008-06-26 | Dan Peters | Novel Diazabicyclic Aryl Derivatives And Their Medical Use |
CN1922176A (zh) * | 2004-12-10 | 2007-02-28 | 艾博特公司 | 稠合的双环杂环取代的奎宁环衍生物 |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US8906360B2 (en) | 2005-07-22 | 2014-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US7897766B2 (en) * | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
CA2632642A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
WO2008002594A2 (en) | 2006-06-27 | 2008-01-03 | Neuroprotection For Life Corp. | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors |
FR2905009A1 (fr) | 2006-08-18 | 2008-02-22 | Servier Lab | Methode de criblage de composes aux proprietes anti-amyloide |
EP2083921A2 (en) | 2006-09-04 | 2009-08-05 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
AU2007309390A1 (en) | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Methods and combination therapies for treating Alzheimer's disease |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
AU2008212171A1 (en) | 2007-02-09 | 2008-08-14 | Astellas Pharma Inc. | Aza-bridged-ring compound |
WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
WO2008112177A2 (en) | 2007-03-08 | 2008-09-18 | Genizon Biosciences, Inc. | Genemap of the human genes associated with schizophrenia |
US8163916B2 (en) | 2007-03-23 | 2012-04-24 | Abbott Laboratories | Azaadamantane ester and carbamate derivatives and methods of use thereof |
CA2682323A1 (en) | 2007-04-02 | 2008-10-09 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
WO2009017454A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
WO2009058120A1 (en) | 2007-11-02 | 2009-05-07 | Sri International | Nicotinic acetylcholine receptor modulators |
US8697722B2 (en) | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
WO2009066735A1 (ja) | 2007-11-20 | 2009-05-28 | Nissan Chemical Industries, Ltd. | 2-アザアダマンタン類の製造方法 |
DE102007058504A1 (de) | 2007-12-05 | 2009-07-09 | Acino Ag | Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR) |
CN101977628A (zh) | 2008-02-13 | 2011-02-16 | 塔加西普特公司 | α7烟碱激动剂和抗精神病药的组合 |
US20090239901A1 (en) | 2008-03-19 | 2009-09-24 | Merouane Bencherif | Method and compositions for treatment of cerebral malaria |
WO2009140201A1 (en) | 2008-05-12 | 2009-11-19 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
FR2931677B1 (fr) | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
CA2727141A1 (en) | 2008-06-13 | 2009-12-17 | Centre For Addiction And Mental Health | Compositions and methods for modulating nicotinic/nmda receptor function |
WO2010030887A1 (en) | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
EP2344636B1 (en) | 2008-10-09 | 2017-12-06 | Howard Hughes Medical Institute | Novel chimeric ligand-gated ion channels and methods of use thereof |
US20110262407A1 (en) | 2008-11-11 | 2011-10-27 | Targacept, Inc. | Treatment with alpha7 selective ligands |
CA2750928A1 (en) | 2009-01-28 | 2010-08-05 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
CA2769209A1 (en) | 2009-07-31 | 2011-02-03 | Biocryst Pharmaceuticals, Inc. | Pyrrolo [1,2-b] pyridazine derivatives as janus kinase inhibitors |
MX2012002209A (es) | 2009-08-21 | 2012-07-25 | Univ Florida | Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos. |
EP2485733A4 (en) | 2009-10-09 | 2014-06-18 | Afraxis Holdings Inc | METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
WO2011058582A1 (en) | 2009-11-16 | 2011-05-19 | Orchid Research Laboratories Ltd. | Histone deacetylase inhibitors for the treatment of fungal infections |
SG2014013460A (en) | 2010-09-23 | 2014-09-26 | Abbvie Inc | Monohydrate of an azaadamantane derivative |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
-
2007
- 2007-11-05 US US11/935,157 patent/US8314119B2/en active Active
- 2007-11-06 PL PL07863920T patent/PL2099795T3/pl unknown
- 2007-11-06 KR KR1020147007297A patent/KR20140054300A/ko active IP Right Grant
- 2007-11-06 PT PT78639200T patent/PT2099795E/pt unknown
- 2007-11-06 DK DK07863920.0T patent/DK2099795T3/en active
- 2007-11-06 CA CA2668962A patent/CA2668962C/en not_active Expired - Fee Related
- 2007-11-06 UA UAA200905813A patent/UA96961C2/uk unknown
- 2007-11-06 NZ NZ577474A patent/NZ577474A/en not_active IP Right Cessation
- 2007-11-06 MX MX2012005921A patent/MX340064B/es unknown
- 2007-11-06 EP EP07863920.0A patent/EP2099795B1/en active Active
- 2007-11-06 RU RU2009121564/04A patent/RU2450002C2/ru not_active IP Right Cessation
- 2007-11-06 TW TW096141946A patent/TWI511729B/zh not_active IP Right Cessation
- 2007-11-06 MX MX2009004813A patent/MX2009004813A/es active IP Right Grant
- 2007-11-06 KR KR1020147024403A patent/KR20140116558A/ko active IP Right Grant
- 2007-11-06 CN CN201310452391.6A patent/CN103554107B/zh not_active Expired - Fee Related
- 2007-11-06 KR KR1020157006394A patent/KR101654073B1/ko active IP Right Grant
- 2007-11-06 WO PCT/US2007/083687 patent/WO2008058096A2/en active Application Filing
- 2007-11-06 KR KR1020097011732A patent/KR101636439B1/ko active IP Right Grant
- 2007-11-06 NZ NZ618134A patent/NZ618134A/en not_active IP Right Cessation
- 2007-11-06 ES ES07863920.0T patent/ES2551117T3/es active Active
- 2007-11-06 SG SG2011082419A patent/SG176473A1/en unknown
- 2007-11-06 AU AU2007316480A patent/AU2007316480B2/en not_active Ceased
- 2007-11-06 NZ NZ589813A patent/NZ589813A/xx not_active IP Right Cessation
- 2007-11-06 MY MYPI20091774A patent/MY148253A/en unknown
- 2007-11-06 NZ NZ600178A patent/NZ600178A/en not_active IP Right Cessation
- 2007-11-06 BR BRPI0718028-4A patent/BRPI0718028A2/pt not_active IP Right Cessation
- 2007-11-06 JP JP2009535497A patent/JP5275246B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-23 CR CR10743A patent/CR10743A/es unknown
- 2009-05-05 IL IL198587A patent/IL198587A/en not_active IP Right Cessation
- 2009-06-04 CO CO09057911A patent/CO6210720A2/es active IP Right Grant
- 2009-06-04 EC EC2009009388A patent/ECSP099388A/es unknown
- 2009-06-05 ZA ZA2009/03944A patent/ZA200903944B/en unknown
- 2009-06-08 NO NO20092181A patent/NO20092181L/no not_active Application Discontinuation
-
2010
- 2010-02-01 HK HK10101088.9A patent/HK1133645A1/xx not_active IP Right Cessation
- 2010-11-29 ZA ZA2010/08549A patent/ZA201008549B/en unknown
-
2011
- 2011-09-29 DO DO2011000301A patent/DOP2011000301A/es unknown
-
2012
- 2012-01-27 RU RU2012102908/04A patent/RU2012102908A/ru not_active Application Discontinuation
- 2012-10-16 US US13/653,192 patent/US8987453B2/en not_active Expired - Fee Related
-
2013
- 2013-01-22 JP JP2013008959A patent/JP5562449B2/ja not_active Expired - Fee Related
- 2013-04-17 PH PH12013500745A patent/PH12013500745A1/en unknown
- 2013-05-13 ZA ZA2013/03483A patent/ZA201303483B/en unknown
- 2013-07-25 IL IL227668A patent/IL227668A/en not_active IP Right Cessation
-
2014
- 2014-06-09 JP JP2014118329A patent/JP5727651B2/ja not_active Expired - Fee Related
- 2014-06-13 CR CR20140277A patent/CR20140277A/es unknown
-
2015
- 2015-01-20 DO DO2015000014A patent/DOP2015000014A/es unknown
- 2015-02-17 US US14/624,517 patent/US20150158867A1/en not_active Abandoned
- 2015-04-02 JP JP2015075967A patent/JP2015143260A/ja active Pending
- 2015-10-20 DO DO2015000264A patent/DOP2015000264A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009004813A (es) | Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos. | |
UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
MX2009000884A (es) | Derivados de piridizinona. | |
MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
MX2010008714A (es) | Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos. | |
TW200640867A (en) | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | |
UA103319C2 (en) | Thiazole- and oxazole-benzene sulfonamide compounds | |
PH12013500365A1 (en) | Anti-infective agents and uses thereof | |
MX2009010207A (es) | Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c. | |
EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
UA86119C2 (ru) | Амидные пролекарства гемцитабина, их композиции и применение | |
JO3007B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
WO2009145996A3 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
HK1133642A1 (en) | Azaadamantane ester and carbamate derivatives and methods of use thereof | |
MX2009006750A (es) | Derivados de azaadamantano espirociclicos y metodos de uso. | |
ATE517873T1 (de) | 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten | |
MX2010004546A (es) | Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina. | |
TN2009000536A1 (en) | Novel herbicides | |
MX2009010176A (es) | Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos. | |
MX2009000198A (es) | Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo. | |
DE602008002598D1 (en) | Cyclohexylderivate | |
HK1131609A1 (en) | Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof |